INSM
Insmed·NASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
Signals Analysis
Bullish signal 3
Bearish signal 4
Consensus Rating "Strong Buy"
Bearish Engulfing
Ample Liquidity
High Gross Profit Margin
Significant Net Income Decline
EPS Below Expectations
Revenue Below Expectations
Key Stats
0.0000DAY`S RANGE0.0000
0.000052 WK RANGE0.0000
0.0000
0.0000
--
--
--
--
--
--
--
--
--
--
--
--
--
--
0.0000
0.0000
0.0000
0.0000
About INSM
Insmed Incorporated
A biopharmaceutical company focused on developing and commercializing innovative therapies for rare and serious diseases
700 US Highway 202/206, Bridgewater, New Jersey 08807
--
Insmed Incorporated is a biopharmaceutical company focused on developing inhaled therapies to combat life-threatening lung diseases for patients. The company's flagship products ARIKACE and amikacin liposome inhalation are an inhaled antibiotic therapy, proving that anti-infectives can improve the efficacy, safety and convenience of the therapy in the treatment of severe lung infections. The company was established in Commonwealth Virginia on November 29, 1999.
Earnings Call
Q1/2025
Estimate EPS-1.36
Actual EPS-1.42
Estimate Revenue92.09M
Actual Revenue92.82M
Insmed's 2025 Q1 Earnings Call: Unpacking Contradictions in Brensocatib Pricing and TPIP Development
May 19,2025 06:10
Earnings Decrypt
Earnings Decrypt
Q2/2025
Estimate EPS-1.31
Actual EPS-1.7
Estimate Revenue104.31M
Actual Revenue107.40M
Insmed's Q2 2025: Key Contradictions in Bronchiectasis Strategy, Pricing, and Market Access
Aug 07,2025 06:08
Earnings Decrypt
Earnings Decrypt
Q3/2025
Estimate EPS-1.37
Actual EPS-1.75
Estimate Revenue115.49M
Actual Revenue142.00M
Insmed's Q3 2025 Earnings Call: Contradictions Emerge on Payer Criteria, Patient Access, and Market Strategy
Oct 30,2025 12:01
Earnings Decrypt
Earnings Decrypt
Company Financials
EPS
INSM has released its 2025 Q3 earnings. EPS was reported at -1.75, versus the expected -1.37, missing expectations. The chart below visualizes how INSM has performed over recent quarters, highlighting trends in earnings surprises.
Revenue & Expenses
INSM has released its 2025 Q3 earnings report, with revenue of 142.34M, reflecting a YoY change of 52.36%, and net profit of -370.02M, showing a YoY change of -67.79%. The Sankey diagram below clearly presents INSM's revenue sources and cost distribution.
Forecast
Wall Street Opinions
Price Target
Volume Profile
Trade Flow Insight
Seasonals
Community Forum
Loading...
Related News
No articles available
